Retifanlimab
Monoclonal antibody
Evidence outlook
Approved: Merkel Cell Carcinoma, Squamous Cell Carcinoma of the Anal Canal
Regulatory approval supersedes design-level evidence grading; the trials behind approval are preserved below as the drug's evidence history.
Also in development:Non-Small Cell Lung Cancer · Phase 3 · investigational in the US
Also approved (3)
- Zynyz in combination with carboplatin and paclitaxel for first-line treatment of adults with metastatic or inoperable locally recurrent squamous cell carcinoma of the anal canal
- Zynyz monotherapy for first-line treatment of adults with metastatic or recurrent locally advanced Merkel cell carcinoma not amenable to curative surgery or radiation therapy (MAH Incyte Biosciences Distribution B.V.); a squamous cell carcinoma of the anal canal indication was added later
- Treatment of unresectable advanced or recurrent squamous cell carcinoma of the anal canal
How the evidence outlook works ↗
Featured trials
The studies most instrumental to this drug's clinical progression, individually graded on design and result. The complete registry, including every study not featured here, is listed below.
| Trial | Phase | Endpoint | Key result | Signal | Source |
|---|---|---|---|---|---|
NCT03599713 NCT03599713 · Merkel Cell Carcinoma Registry: NCT03599713 | 2 | Objective Response Rate (ORR) (up to 26.8 months) 2022-01-21 | Completed. Key figures are not recorded here. | not yet graded | link ↗ |
All registered studies
Every ClinicalTrials.gov study of this drug's own program. Studies backing a featured trial above are marked Featured; the rest aren't individually graded. Filter by which indication a study was run for, then browse by phase.
Phase 3 (4)
What this study did
What this study did
What this study did
What this study did
Phase 2/3 (2)
What this study did
What this study did
Phase 2 (31)
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
Phase 1/2 (14)
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
Phase 1 (20)
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
Competitive landscape
Other PD-1 drugs
Cemiplimab, Dostarlimab, Nivolumab, Opdivo Qvantig, Pembrolizumab and 21 more. Compare all 27 PD-1 drugs
This mechanism is crowded: 26 other tracked programmes target it, none of them ahead of this one.
This drug's own stage for Merkel Cell Carcinoma: Approved. Competitors below are sorted furthest-along first.
| Drug | Stage | Modality | Mechanism | Evidence signal | Reported efficacygraded featured trials | |
|---|---|---|---|---|---|---|
| Retifanlimab: this drug | Approved | Monoclonal antibody | PD-1 | not yet graded | No reviewed efficacy summary in this indication | |
| Avelumab | Approved | Monoclonal antibody | PD-L1 | not yet graded | No reviewed efficacy summary in this indication | |
| Pembrolizumab | Approved | Monoclonal antibody | PD-1 | Weak signal | NCT03783078: Objective Response Rate (ORR) (Up to ~34 months): Pembrolizumab 200 mg 49.1 Percentage of participants (95% CI 35.4 to 62.9) NCT02267603: Objective Response Rate (ORR) Defined as the Proportion of Patients Who Have Achieved Complete Response (CR) or Partial Response (PR) According to Response Evaluation Criteria in Solid Tumors (RECIST) Version 1.1 (Up to 3 years): Treatment (Pembrolizumab) — Number participants with partial response (PR): 16 Participants; Number participants with complete response (CR): 12 Participants; Combined total participants with either PR or CR: 28 Participants | |
| Iparomlimab (QL1604) | Phase 3(overall) | Monoclonal antibody | PD-1 | not yet graded(overall) | No reviewed efficacy summary in this indication | |
| IFx-2.0 | Phase 2/3 | Gene therapy / editing | Innate immune activation (intralesional plasmid DNA) | not yet graded | No reviewed efficacy summary in this indication | |
| SHR-3045 | Phase 2(overall) | Undisclosed | PD-1 | not yet graded(overall) | No reviewed efficacy summary in this indication | |
| Bmab1700 | Phase 1(overall) | Monoclonal antibody | PD-1 | not yet graded(overall) | No reviewed efficacy summary in this indication |
Compare side by side
17 further pairs are tracked; the rosters on each shared mechanism and indication page list every rival in the race.
Upcoming events
(25 total)
Estimated primary-completion dates from ClinicalTrials.gov. These are registry estimates, never confirmed readout dates; they can move as trials progress.
Follow Retifanlimab to get an email as a readout nears, when a date moves, or when a study changes status. Needs a free account.
Add these readouts to your calendar: Apple or Outlook · Google Calendar · .ics link. The calendar updates when a registry date moves.
2026 (2)
2027 (13)
January 2027 (2)
March 2027 (1)
What to watch
April 2027 (1)
What to watch
June 2027 (3)
What to watch
What to watch
What to watch
September 2027 (1)
What to watch
October 2027 (1)
What to watch
December 2027 (4)
What to watch
What to watch
What to watch
What to watch
2028 (4)
January 2028 (1)
What to watch
March 2028 (1)
What to watch
August 2028 (1)
What to watch
December 2028 (1)
What to watch
2029 (4)
January 2029 (1)
What to watch
November 2029 (1)
What to watch
December 2029 (2)
What to watch
What to watch
2030 (1)
October 2030 (1)
What to watch
2031 (1)
May 2031 (1)
What to watch
Regulatory and conference events
(1)
Filings, regulator decisions, scientific presentations, topline results and licensing deals, each from a dated source. When a source gives only the month, the month is shown.
Recent